Claims for Patent: 7,303,747

✉ Email this page to a colleague

Summary for Patent: 7,303,747

Title:	Use of VEGF inhibitors for treatment of eye disorders
Abstract:	Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
Inventor(s):	Wiegand; Stanley J. (Croton-on-Hudson, NY), Papadopoulos; Nicholas J. (LaGrangeville, NY), Yancopoulos; George D. (Yorktown Heights, NY), Fandl; James P. (LaGrangeville, NY), Daly; Thomas J. (New City, NY)
Assignee:	Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:	11/218,234
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,303,747
Patent Claims:	1. A therapeutic method for treating or ameliorating an eye disorder, comprising administering a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:6, wherein the eye disorder is associated with choroidal neovascularization, vascular leak, or retinal edema, and wherein administration is systemic. 2. The therapeutic method of claim 1, wherein the eye disorder is age related macular degeneration or diabetic retinopathy. 3. A method for the treatment of a human subject diagnosed with age-related macular degeneration, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) inhibitor to the human subject, the method comprising: (a) administering to the subject an initial dose of at least approximately 25-4000 micrograms VEGF inhibitor protein per eye; and (b) administering to the subject a plurality of subsequent doses of the VEGF inhibitor protein in an amount that is approximately the same or less than the initial dose, wherein the subsequent doses are separated in time from each other by at least two weeks, wherein the VEGF inhibitor is a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:6 and administration of the VEGF inhibitor is systemic. 4. The method of claim 3, wherein the initial dose is at least approximately 1000 micrograms of VEGF inhibitor protein. 5. The method of claim 4, wherein the subsequent doses are separated in time from each other by at least four weeks. 6. The method of claim 5, wherein the subsequent doses are separated in time from each other by at least 3 to 6 months.

Details for Patent 7,303,747

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	November 18, 2011	⤷ Sign Up	2039-02-26
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	August 16, 2018	⤷ Sign Up	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 7,303,747

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
Argentina	044938	⤷ Sign Up
Austria	E293164	⤷ Sign Up
Austria	E417928	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.